← Back to Search

N/A

Omit breast radiation for Breast Cancer

Phase 2
Waitlist Available
Led By Armando Giuliano, MD, FACS, FRCSEd
Research Sponsored by Armando Giuliano
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of consent. assessed up to 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying if women with HER2+ breast cancer who have no remaining cancer after surgery can safely skip radiation treatment.

Eligible Conditions
  • HER2-positive Breast Cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of consent. assessed up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of consent. assessed up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of enrolling patients measured by proportion of recruited patients to participate in the trial

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Omit breast radiationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Armando GiulianoLead Sponsor
Armando Giuliano, MD, FACS, FRCSEdPrincipal InvestigatorCedars-Sinai Medical Center

Media Library

Omit breast radiation (N/A) Clinical Trial Eligibility Overview. Trial Name: NCT05371860 — Phase 2
Breast Cancer Research Study Groups: Omit breast radiation
Breast Cancer Clinical Trial 2023: Omit breast radiation Highlights & Side Effects. Trial Name: NCT05371860 — Phase 2
Omit breast radiation (N/A) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05371860 — Phase 2
~0 spots leftby Oct 2028